High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome
Abstract Background High‐dose‐rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1450 |
| _version_ | 1818332884374650880 |
|---|---|
| author | Iosif Strouthos Efstratios Karagiannis Nikolaos Zamboglou Konstantinos Ferentinos |
| author_facet | Iosif Strouthos Efstratios Karagiannis Nikolaos Zamboglou Konstantinos Ferentinos |
| author_sort | Iosif Strouthos |
| collection | DOAJ |
| description | Abstract Background High‐dose‐rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one of the most active clinical research areas. Recent findings This review encompasses all the current evidence to support the use of HDR BRT in various clinical scenario and shines light to the HDR BRT rationale, as an ultimately conformal dose delivery method enabling safe dose escalation to the prostate. Conclusion Valid long‐term data, both in regard to the oncologic outcomes and toxicity profile, support the current clinical indication spectrum of HDR BRT. At the same time, this serves as solid, rigid ground for emerging therapeutic applications, allowing the technique to remain in the spotlight alongside stereotactic radiosurgery. |
| first_indexed | 2024-12-13T13:42:50Z |
| format | Article |
| id | doaj.art-ab709cb97fda41c3bdf3a2001fdfab2d |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-12-13T13:42:50Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-ab709cb97fda41c3bdf3a2001fdfab2d2022-12-21T23:43:32ZengWileyCancer Reports2573-83482022-01-0151n/an/a10.1002/cnr2.1450High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcomeIosif Strouthos0Efstratios Karagiannis1Nikolaos Zamboglou2Konstantinos Ferentinos3Department of Radiation Oncology German Oncology Center Limassol CyprusDepartment of Radiation Oncology German Oncology Center Limassol CyprusDepartment of Radiation Oncology German Oncology Center Limassol CyprusDepartment of Radiation Oncology German Oncology Center Limassol CyprusAbstract Background High‐dose‐rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one of the most active clinical research areas. Recent findings This review encompasses all the current evidence to support the use of HDR BRT in various clinical scenario and shines light to the HDR BRT rationale, as an ultimately conformal dose delivery method enabling safe dose escalation to the prostate. Conclusion Valid long‐term data, both in regard to the oncologic outcomes and toxicity profile, support the current clinical indication spectrum of HDR BRT. At the same time, this serves as solid, rigid ground for emerging therapeutic applications, allowing the technique to remain in the spotlight alongside stereotactic radiosurgery.https://doi.org/10.1002/cnr2.1450combined with EBRThigh‐dose‐rateinterstitial brachytherapymonotherapyprostate cancersalvage |
| spellingShingle | Iosif Strouthos Efstratios Karagiannis Nikolaos Zamboglou Konstantinos Ferentinos High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome Cancer Reports combined with EBRT high‐dose‐rate interstitial brachytherapy monotherapy prostate cancer salvage |
| title | High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome |
| title_full | High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome |
| title_fullStr | High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome |
| title_full_unstemmed | High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome |
| title_short | High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome |
| title_sort | high dose rate brachytherapy for prostate cancer rationale current applications and clinical outcome |
| topic | combined with EBRT high‐dose‐rate interstitial brachytherapy monotherapy prostate cancer salvage |
| url | https://doi.org/10.1002/cnr2.1450 |
| work_keys_str_mv | AT iosifstrouthos highdoseratebrachytherapyforprostatecancerrationalecurrentapplicationsandclinicaloutcome AT efstratioskaragiannis highdoseratebrachytherapyforprostatecancerrationalecurrentapplicationsandclinicaloutcome AT nikolaoszamboglou highdoseratebrachytherapyforprostatecancerrationalecurrentapplicationsandclinicaloutcome AT konstantinosferentinos highdoseratebrachytherapyforprostatecancerrationalecurrentapplicationsandclinicaloutcome |